Keyphrases
Pharmacokinetics
77%
N-acetylcysteine
58%
Status Epilepticus
43%
Levetiracetam
43%
Fosphenytoin
38%
Established Status Epilepticus
33%
Tolerability
32%
Epilepsy
32%
Baclofen
31%
Lateral Fluid Percussion
29%
Benzodiazepines
28%
Treatment Trials
27%
Status Epilepticus Treatment
27%
Canine
22%
Parkinson's Disease
21%
Glutathione
19%
Intravenous Administration
18%
Post-traumatic Epilepsy
18%
Valproic Acid
18%
Phenytoin
18%
New-onset Refractory Status Epilepticus (NORSE)
18%
Traumatic Brain Injury
18%
Seizure
17%
Rat Model
15%
Blood Samples
14%
Clinical Tolerance
14%
Early Seizures
14%
Healthy Volunteers
14%
Early-life Exposure
14%
Brain Uptake
14%
Sodium Selenite
14%
Infantile Spasms
14%
Older Adults
12%
P-glycoprotein (P-gp)
12%
Nave
11%
Diazepam
11%
Pharmacodynamics
11%
Drug Exposure
10%
Temporal Lobe
10%
Clinical Pharmacology
10%
High Dose
10%
Route of Administration
9%
Ursodeoxycholic Acid
9%
Antiepileptogenic
9%
Cysteine
9%
Hypoglycemia
9%
Baclofen Withdrawal
9%
Seizure Cessation
9%
Loading Dose
9%
Seizure Emergencies
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Epileptic State
75%
Acetylcysteine
58%
Levetiracetam
42%
Fosphenytoin Sodium
37%
Baclofen
36%
Tolerability
32%
Sodium Valproate
27%
Benzodiazepine
25%
Glutathione
25%
Parkinson's Disease
21%
Pharmacodynamics
20%
Phenytoin
19%
Diazepam
16%
Biological Marker
15%
Traumatic Brain Injury
15%
Normal Human
15%
Hypoglycemia
14%
Rat Model
14%
Infantile Spasm
14%
Drug Administration
11%
Anticonvulsive Agent
11%
Brexanolone
10%
Prodrug
10%
Dipeptidyl Carboxypeptidase
10%
Cysteine
9%
Clinical Trial
9%
Lorazepam
8%
Midazolam
8%
Intubation
8%
Gaucher's Disease
8%
Antioxidant
8%
Muscle Spasm
7%
Bioavailability
7%
Randomized Controlled Trial
7%
Drug Development
7%
Buprenorphine
7%
Saquinavir
7%
Ketamine
7%
Automutilation
7%
Biomarker Study
7%
Plasma Protein
7%
Canine Model
7%
Ursodeoxycholic Acid
7%
Methadone
7%
Topiramate
7%
Repurposing
7%
Focal Epilepsy
7%
Celastrol
7%
Edaravone
7%